Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates

PRECISION1 tumor-agnostic trial unlikely to meet regulatory threshold to support an accelerated approval and will be halted Aadi will focus on FYARRO® commercial business for its approved indication, PEComa, and conduct a comprehensive strategic review to maximize shareholder value To further preserve cash position, Aadi will adjust ongoing Phase 2 trials and reduce R&D headcount by 80%, thereby extending cash runway into at least 2H 2026LOS ANGELES, Aug. 20, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASD ...